Despite detractors, Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

Lilly is the latest to approach the coveted Alzheimer’s approval, but a slate of drugmakers are lining up clinical trials in amyloid and tau to take a shot at improving patient outcomes.